Bearish
Pfizer's stock declines 1.2% amid cautious analyst sentiment and CFO departure
Pfizer's stock experienced a 1.2% decline, closing at $24.75 on July 20, 2026. This downturn is attributed to cautious analyst sentiment, with several firms recently lowering price targets, and the announcement of CFO Dave Denton's departure, effective August 15. Despite reaffirming its 2026 revenue guidance of $59.5 billion to $62.5 billion, the stock's consensus rating remains 'Hold' with an average target price of $28.50.
Key points
- Analysts have recently reduced price targets for Pfizer, contributing to a cautious outlook.
- The announcement of CFO Dave Denton's departure has raised concerns among investors.
- Pfizer has reaffirmed its 2026 revenue guidance, indicating stability in its financial outlook.
Sources
AI-generated from public news sources. Not financial advice.
